An ASCVD risk score estimates the chance of a first heart attack or stroke in the next 10 years, from age, sex, cholesterol, blood pressure, smoking, and diabetes. It is a population estimate applied to one person, and it is used to start a conversation about prevention, not to deliver a verdict. Under the pooled cohort equations used by the calculator on the hub page, and the 2018 ACC/AHA cholesterol guideline, a risk under 5% is low, 5% to 7.4% is borderline, 7.5% to 19.9% is intermediate, and 20% or more is high, and each band carries a different guideline conversation about lifestyle and statin therapy. This guide explains the bands, the inputs that move the number, the risk-enhancing factors that personalise it, and the limits that keep the percentage in its place. It is general information only, not medical advice, and no treatment decision should be made from a calculator result alone.

What the score estimates

ASCVD stands for atherosclerotic cardiovascular disease: heart attacks and strokes caused by plaque building up in arteries. The 10-year ASCVD risk estimates the probability that a person without established cardiovascular disease will have a first hard ASCVD event, a fatal or nonfatal heart attack or a fatal or nonfatal stroke, in the next 10 years. It is expressed as a percentage: 7.5% means that, among 100 people with the same risk-factor profile, about 7 or 8 would be expected to have such an event in 10 years, and about 92 or 93 would not. The percentage describes a group, and it cannot say which individuals in the group will be affected, which is the fundamental limit of every risk estimate, and the reason the guideline frames the result as a risk discussion rather than a prediction about one person.

The calculator on the hub page uses the pooled cohort equations, developed from several long-running United States cohort studies, which estimate risk from age, sex, race group as used in the original equations, total cholesterol, HDL cholesterol, systolic blood pressure and whether it is treated, diabetes, and smoking status. The equations were derived for adults 40 to 75 years old, and their accuracy outside that range, and in populations unlike the derivation cohorts, is less certain. Newer equations, the PREVENT equations adopted in the 2026 ACC/AHA dyslipidemia guideline, estimate risk for adults 30 to 79, include kidney function and blood sugar measures, do not use race, and use different risk cutoffs. This guide follows the pooled cohort bands the hub calculator shows, and notes the newer equations so a reader whose clinician uses them is not confused by different thresholds: the bands belong to the equation that produced them, and percentages from different equations are not interchangeable.

The four bands, and what each means

The 2018 ACC/AHA cholesterol guideline sorts every 10-year pooled cohort risk into one of four bands. Low risk is under 5%: heart-healthy lifestyle is emphasised, and a statin is not usually part of the discussion at this level. Borderline risk is 5% to 7.4%: the clinician and patient look together for risk-enhancing factors, and a moderate-intensity statin can be considered if they are present. Intermediate risk is 7.5% to 19.9%: the guideline favours a discussion about starting a moderate-intensity statin, aiming for at least a 30% reduction in LDL cholesterol, with risk-enhancing factors favouring initiation or intensification. High risk is 20% or more: high-intensity statin therapy is favoured, aiming for at least a 50% reduction in LDL cholesterol, and additional lipid-lowering therapy is considered if goals are not met. The hub page shows the same four bands on its result scale, stretched at the low end, because that is where most adults land and where the boundaries actually bite.

Pooled cohort equation bands, 2018 ACC/AHA cholesterol guideline, adults 40 to 75. General information only.

A good score, in the sense the question asks, is a low score for the person age and circumstances, and the band boundaries are the reference, not a pass mark. A 45-year-old at 3% is low and reassuring, and the work is maintenance. A 70-year-old at 12% is intermediate, and the same percentage in a younger person would sit differently, because the equation gives age the largest weight and a 70-year-old starts from a higher baseline whatever else is true. The band, not the raw percentage alone, carries the guideline meaning, and the trend matters too: a risk that falls from 12% to 8% after treatment and lifestyle change is progress, even though the band may not have changed, and a risk that rises across the borderline-intermediate boundary deserves attention even though the absolute change is small.

What moves the number

Age moves the number most. The pooled cohort equations give age a larger weight than any other single input, because cardiovascular risk rises steeply with age, and two people with identical cholesterol, blood pressure, and habits will have very different risks at 45 and at 70. That is not a flaw in the equation; it is the epidemiology. It does mean that a low risk at 45 is partly youth, and that maintaining the same risk factors will still produce a higher risk at 65, because the age term has moved. The hub guide works one lever at a time from the same man, changing one input while holding the rest, and the age lever is the largest single move in that exercise, which is worth seeing before any other input is judged.

After age, the modifiable inputs move the number in the expected directions. Higher total cholesterol and lower HDL cholesterol raise risk; higher systolic blood pressure raises it, and treated blood pressure reads higher than untreated pressure at the same number in the equations, because treatment marks a person whose pressure was high enough to need treatment, a history the equation encodes. Smoking raises risk substantially, and diabetes raises it substantially. The non-modifiable inputs, sex and the race group used in the original equations, shift the baseline: the equations are sex-specific and race-specific as derived, and the hub calculator offers the race-group option the equations require, with the limitations of that approach stated in its guide. No input should be changed on paper to game the number: the calculator is a mirror, and changing an input without changing the body it describes only fogs the mirror.

Risk-enhancing factors

Risk-enhancing factors are conditions and markers that the pooled cohort equations do not fully capture, and that favour starting or intensifying statin therapy, particularly in the borderline and intermediate bands. They include a family history of premature ASCVD, a parent or sibling with heart disease at a young age, persistently elevated LDL cholesterol of 160 mg/dL or more, metabolic syndrome, chronic kidney disease, chronic inflammatory conditions such as rheumatoid arthritis, psoriasis, or lupus, and a history of preeclampsia or premature menopause. Laboratory markers include elevated lipoprotein(a), elevated apolipoprotein B, elevated high-sensitivity C-reactive protein, and persistently elevated triglycerides, and an ankle-brachial index below 0.9 marks peripheral artery disease. The presence of one or more enhancers does not change the percentage, but it changes the conversation the percentage starts: a borderline risk with enhancers is treated more like an intermediate risk, and an intermediate risk with enhancers is treated more firmly.

Two conditions bypass the risk calculation altogether in the guideline. An LDL cholesterol of 190 mg/dL or more, in adults 20 to 75, favours high-intensity statin therapy without a 10-year risk estimate, because the level itself marks severe hypercholesterolemia, often familial. Diabetes in adults 40 to 75 favours at least moderate-intensity statin therapy regardless of the calculated risk, with high-intensity therapy reasonable where multiple risk factors are present. Those are guideline rules for clinicians to apply, stated here so a reader with a very high LDL or with diabetes understands why the calculator percentage is not the deciding figure in their case, and why the clinician discussion starts from a different place.

Statin thresholds: how the guideline uses the bands

Statin therapy is the first-line drug treatment for primary prevention in the guideline, and the bands decide the intensity of the conversation, not a prescription. In intermediate-risk adults, the guideline favours moderate-intensity statin therapy, with an LDL cholesterol reduction of 30% or more, and for optimal risk reduction, especially in high-risk patients, a reduction of 50% or more. In high-risk adults, high-intensity therapy is favoured from the start. In borderline-risk adults, a moderate-intensity statin can be considered where risk enhancers are present, and in low-risk adults lifestyle measures suffice unless a separate indication, such as an LDL of 190 mg/dL or more, or diabetes, applies. The intensity labels refer to the expected LDL reduction: moderate intensity reduces LDL by 30% to 49%, high intensity by 50% or more, and the choice of agent and dose, the monitoring, and the handling of side effects and interactions belong to the clinician, with the patient preferences in the discussion.

The guideline insists on a clinician-patient risk discussion before starting therapy, covering the risk factors, the potential benefit, the potential adverse effects and drug interactions, the cost, and the patient preferences. That discussion is not a formality: statins benefit people in proportion to their absolute risk, so the same relative reduction is worth more, in events prevented, to a person at 20% risk than to a person at 3% risk, and the balance of benefit against harm, cost, and burden shifts accordingly. A calculator result that is never discussed is an unfinished result, and a statin started or refused on the percentage alone, without the discussion, misses the part of the guideline that makes the percentage usable.

Coronary calcium: the tie-breaker

Where the decision about statin therapy remains uncertain after the risk estimate and the enhancers, in intermediate-risk adults and selected borderline-risk adults, the guideline states it is reasonable to measure a coronary artery calcium, CAC, score. The CAC score, from a CT scan, measures calcified plaque in the coronary arteries directly, and it reclassifies risk in a way the equations cannot. A score of zero makes it reasonable to withhold statin therapy and reassess in 5 to 10 years, as long as higher-risk conditions, diabetes, family history of premature coronary disease, and cigarette smoking, are absent. A score of 1 to 99 makes it reasonable to initiate statin therapy for patients 55 or older. A score of 100 or higher, or at or above the 75th percentile for age and sex, makes it reasonable to initiate statin therapy. The scan involves radiation and cost, it is not a screening test for everyone, and it should be ordered where the result will change the decision, which is the definition of the uncertain middle bands.

What the number does not capture

The pooled cohort equations do not capture everything that determines risk. They do not measure fitness, diet quality beyond its effect on the inputs, psychosocial stress, sleep, air pollution exposure, or the full family history beyond the enhancer list. They estimate risk for a first hard event in 10 years, and they say nothing about risk beyond 10 years, about lifetime risk, or about non-ASCVD outcomes such as heart failure, which the newer PREVENT equations do include. They were derived in cohorts that may not match the person being assessed, and their calibration, how well predicted risk matches observed risk in a new population, varies. A low score is not immunity, and a high score is not a sentence: both are probabilities over a group, and the individual outcome is binary, event or no event, in a way no percentage can resolve in advance.

Two further limits deserve stating plainly. The equations assume the inputs are measured well: a cholesterol panel drawn during illness, a blood pressure taken once in a hurry, or a smoking status recorded wrongly, all move the result, and the result should be recomputed from careful measurements before it is acted on. And the equations describe risk without treatment: starting a statin, stopping smoking, or lowering blood pressure changes the future risk, and the calculator result is a snapshot of the untreated trajectory, not a forecast that already includes the treatment. Recompute after change, and the movement in the number is the measure of the change, not the original number alone.

Lowering the number: what actually works

The levers that lower the number are the levers that lower the inputs, and they are unglamorous. Stopping smoking lowers risk more, and faster, than any other single change, and the calculator smoking input makes the size of that change visible in one toggle. Lowering systolic blood pressure, through sodium reduction, weight management, activity, and medication where prescribed, lowers the pressure input. Lowering LDL cholesterol, through diet, activity, and statin therapy where indicated, lowers the cholesterol input. Managing diabetes, through the plan agreed with the clinician, lowers the diabetes contribution. Regular aerobic activity, a diet rich in vegetables, fruits, whole grains, and lean protein with minimal trans fats, processed meats, and sweetened drinks, and maintaining a healthy weight, move several inputs at once, which is why lifestyle is emphasised in every band, including high risk, where it accompanies drug therapy rather than replacing it. The hub guide works one lever at a time from the same man, so the size of each change can be seen separately, and the combined change is the sum of the levers actually pulled, not the sum of the levers imagined.

Mistakes: one number, and the wrong population

First, treating the percentage as a personal prediction rather than a group estimate, and either panicking at 15% or relaxing at 4% without the discussion. Second, applying the bands outside the population they were derived for: children, adults under 40, adults over 75, people with established cardiovascular disease, and people with severe kidney disease need different assessments, and the pooled cohort percentage does not govern their care. Third, mixing equations: a PREVENT percentage compared with pooled cohort cutoffs, or a pooled cohort percentage compared with PREVENT cutoffs, misclassifies, because the cutoffs belong to their equations. Fourth, chasing the number by changing inputs on paper, or by a single good measurement, rather than by changing the body. Fifth, starting, stopping, or refusing a statin on the calculator result alone, without the clinician discussion the guideline requires. The number is a tool for the conversation; the conversation is the care.

Frequently asked questions

What is a good ASCVD risk score?

Under the pooled cohort equations, under 5% over 10 years is low risk, which is the reassuring range. 5% to 7.4% is borderline, 7.5% to 19.9% is intermediate, and 20% or more is high. A good score is a low score in the context of age and other factors, and the band, not the raw percentage alone, carries the guideline meaning.

What does a 10-year ASCVD risk of 10% mean?

It means that among 100 people with the same risk-factor profile, about 10 would be expected to have a first heart attack or stroke in the next 10 years, and about 90 would not. It is a group estimate, not a personal prediction, and 10% sits in the intermediate band, where the guideline favours a discussion about moderate-intensity statin therapy.

At what ASCVD risk should you start a statin?

The guideline favours discussing a moderate-intensity statin at intermediate risk, 7.5% to 19.9%, and high-intensity therapy at high risk, 20% or more. At borderline risk, 5% to 7.4%, a statin can be considered where risk-enhancing factors are present. The decision is made in a clinician-patient discussion, not from the percentage alone, and an LDL of 190 mg/dL or more or diabetes changes the starting point.

What is the difference between PCE and PREVENT risk scores?

The pooled cohort equations (PCE) estimate 10-year risk for adults 40 to 75, using age, sex, race group, cholesterol, blood pressure, diabetes, and smoking, with cutoffs at 5%, 7.5%, and 20%. The PREVENT equations, adopted in the 2026 ACC/AHA guideline, cover ages 30 to 79, include kidney function and blood sugar, do not use race, and use different cutoffs. Percentages from the two must not be compared with the other cutoffs.

Does a coronary calcium score of zero mean I do not need a statin?

It can make withholding a statin reasonable, in intermediate or selected borderline risk where the decision is uncertain, with reassessment in 5 to 10 years, as long as higher-risk conditions such as diabetes, family history of premature coronary disease, and smoking are absent. The decision belongs to the clinician discussion, and a zero score is not immunity.

Can ASCVD risk go down?

Yes. Stopping smoking, lowering blood pressure and LDL cholesterol, managing diabetes, regular activity, and a heart-healthy diet all lower the inputs the equations use, and the recomputed risk falls. Age still rises, so the risk may not fall every year, but the change from the levers actually pulled is visible when the score is recomputed from careful measurements.